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Background: Cost of illness studies approximate the economic burden of any disease on the society. Hypertension is one of the most
prevalent vascular diseases and is considered as a main risk factor for cardiovascular diseases. Hypertension is greatly prevalent and
severe in Malaysia. Its care is insufficient. Hypertension detection and treatment is less than satisfactory in Malaysia.
Objective : This study was conducted to quantify the total direct and indirect costs of hypertension management.
Methodology : Data was collected to estimate the direct medical costs for 300 hypertensive patients included health care practitioners’
services, medicines and laboratory tests retrospectively and through follow up process. Indirect costs were estimated as productivity
lost by hypertensive patients. The prevalence and incidence-based approaches were used to estimate the cost of illness of hypertension
disease.
Results : The total direct costs were RM1612.38, RM1741.85 and RM2718.21 for the prehypertensive, stage 1 and stage 2
hypertensive groups respectively. The total indirect costs were RM8078.70, RM6654.52 and RM7511.41.
Conclusion : The direct costs attributable to hypertension disease were higher in higher blood pressure groups. Direct costs of
hypertension are mainly dependant on the costs of antihypertensive agents. Efforts should focus on improving the awareness of the
both clinical and economic benefits of preventing hypertension in the society.
Keywords : Cost, treatment, hypertension, Malaysia.
INTRODUCTION
Hypertension or high blood pressure is one of the most
prevalent vascular diseases and is considered as a main risk
factor for cardiovascular, cerebrovascular, and peripheral
vascular diseases that include coronary disease, stroke,
peripheral artery disease, renal disease, and heart failure.
Hypertension may increase an individual’s risk for one of
these cardiovascular diseases by about two to three times.
1,2
The cost of treating hypertension takes up a huge and
rising share of health care resources.
3
In Malaysia, the prevalence of hypertension in subjects
aged = 15 years was 27.8%. The prevalence increases with
age in both genders. Hypertension was more prevalent in
males than females in subjects aged 15-39 years. Generally,
mean systolic blood pressure was 122 mmHg and mean
diastolic blood pressure was 79 mmHg. Both means
(systolic 124 mmHg and diastolic 80 mmHg) for males
were significantly higher than that for females (systolic
121 mmHg and diastolic 78 mmHg).
4 
This study was
conducted to estimate the direct and indirect costs
attributable to hypertension in Malaysia to better
understanding of the economic burden of hypertension
as hypertension thought to be one of the most expensive
diseases.
METHODOLOGY
Study Design
Both, prevalence-based and incidence-based approaches
were used to estimate the cost of illness of hypertension
disease.
5,7
 The prevalence approach is good for measuring
the effectiveness of cost control and how well health care
expenditure targets are met.
5, 8 
The data were collected
retrospectively for patients who were already been
diagnosed with hypertension and through follow-up for
patients who were diagnosed with hypertension at the
beginning of the study.
A cross-sectional study of a cohort of hypertensive patients
was conducted to determine health care costs among
hypertensive patients according to the hypertension disease
stage (prehypertension, stage 1 and stage 2 hypertension).
The research’s protocol was approved by the Research and
Ethics Committee of the Faculty of Medicine in the
International Islamic University Malaysia.
The study was conducted in Jaya Gading Poliklinik in
Kuantan city, state of Pahang, Malaysia.  A total number
of 300 hypertensive patients with controlled blood pressure
were selected and were considered for this study. Patients
were stratified into three blood pressure groups based on
the blood pressure classification according to JNC 7. First
group included patients with prehypertension, second
group included patients with stage 1 hypertension and
the third group included patients with stage 2
hypertension. Hypertensive patients were placed in the
groups based on their first detected blood pressure reading
stated in their medical file or patient case note.
Data Collection
Three types of data were required and collected using case
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Pre-hypertension Stage 1 hypertension Stage 2 hypertension  
Numbers 
Age 
   <45 
   •45 
 
14 
86 
 
21 
79 
 
16 
84 
Sex 
  Male 
  Female 
 
25 
75 
 
26 
74 
 
32 
68 
Race 
  Malay 
  Others 
 
72 
28 
 
83 
17 
 
84 
16 
Smoking 
     Yes 
     No 
 
12 
88 
 
8 
92 
 
19 
81 
Alcohol 
     Yes 
     No 
 
6 
94 
 
4 
96 
 
7 
93 
Caffeine 
     Yes 
     No 
 
74 
26 
 
81 
19 
 
88 
12 
Exercise 
    Yes 
    No 
 
46 
54 
 
48 
52 
 
40 
60 
 Mean ±SD (Median) 
Age 54.5 ±9.3 (54.5) 52.3 ±9.0 (51.0) 53.7 ±10.2 (54.5) 
BMI 27.5 ±4.8 (27.8)  29.1 ±6.34 (28.4) 27.4 ±4.6 (28.0) 
SBP 116.2 ±2.2 (116.5) 116.0 ±3.9 (116.0) 115.7 ±3.6 (115.4) 
DBP 73.2 ±4.7 (74.7) 72.1 ±5.3 (72.7) 71.9 ±5.3 (72.8) 
Visits 16.1 ±10.4 (13.0) 15.5 ±10.7 (13.5) 13.3 ±9.4 (11.0) 
 
TABLE- 1 Demographic and Clinical Features of Patients in Each Hypertension Category.
SBP: Systolic blood pressure, DBP: Diastolic blood pressure, Visits: Number of visits by the patients to the health care center.
TABLE- 2 Estimated Monthly Direct and Indirect Costs (in year-2008 RM) for  Hypertensive Patients, Stratified By Blood
Pressure Category
 Pre-hypertension Stage 1 hypertension Stage 2 hypertension 
Direct costs Mean ±SD (Median) 
Drugs 8.77 ±16.01 (3.35) 9.64 ±15.17 (3.82) 19.75 ±68.02 (6.02) 
Labs 0.94 ±0.94 (0.65) 0.99 ±1.07 (0.77) 1.08 ±1.30 (0.77) 
Physician 1.77 ±0.83 (1.63) 1.84 ±1.22 (1.61) 1.70 ±0.74 (1.56) 
Pharmacist 1.42 ±0.66 (1.31) 1.48 ±0.97 (1.29) 1.36 ±0.60 (1.25) 
Nurse 1.00 ±0.48 (0.95) 1.07 ±0.71 (0.93) 0.98 ±0.43 (0.90) 
Transport 2.26 ±1.62 (1.70) 2.39 ±1.47 (2.00) 2.33 ±1.21 (2.08) 
Total 16.20 ±16.38 (12.19) 17.43 ±15.50 (11.86) 27.22 ±68.31 (14.05) 
Indirect costs Mean ±SD (Median) 
Productivity lost 176.59 ±86.14 (170.14) 164.73 ±75.90 (158.80) 164.39 ±73.68 (158.80) 
 
record form and a standard questionnaire. A number of
experts in the research fields, (two hypertension specialists
and one in pharmacoeconomics) validated the case record
form and the questionnaire. An informed consent was
prepared in order to help the participants (newly diagnosed
patients) to decide whether to participate in the study or
not. The three types of data were collected: demographic
(age, sex and race, etc), clinical (stage of hypertension,
blood pressure readings, laboratory tests’ results, treatment
options, etc) and economic (drugs, diagnostic procedures,
laboratory tests, physician’s, pharmacist’s and nurse’s,
transportation cost, monthly salary, etc) data.
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TABLE- 3 Monthly Mean Total Direct Costs
Hypertension stage Mean ±SD (Median) Mean Rank* 
Pre- 16.20 ±16.38 (12.19) 136.5 
Stage 1 17.43 ±15.50 (11.86) 145.9 
Stage 2 27.22 ±68.31 (14.05) 169.08 
 *Kruskal-Wallis Test (P <0.024)
TABLE- 4 Loss of Productivity Due to Hypertension
Hypertension stage Mean ±SD (Median) Mean Rank* 
Pre- 176.59 ±86.14 (170.14) 151.82 
Stage 1 164.73 ±75.90 (158.80) 144.76 
Stage 2 164.39 ±73.68 (158.80) 154.93 
 *Kruskal-Wallis Test (P <0.65)
TABLE- 5 Economic Burden of Hypertension, Malaysia, 2007, Data are in Malaysian Ringgit.
 
Pre- 
(N=100) 
% Stage 1 (N=100) % 
Stage 2 
(N=100) 
% 
Direct costs 1612.38 16% 1741.85 21% 2718.21 27% 
Indirect costs 8078.70 84% 6654.52 79% 7511.41 73% 
Total 9691.08 100.0 8396.37 100.0 10229.62 100.0 
 
Data Analysis
A variety of descriptive statistics such as mean, standard
deviation, median were calculated to describe some parts
of the results. Typical health cost data are known to be
right-skewed, which in small samples may violate the
parametric measures that rely on normal distribution
 9,10
and thus nonparametric testing (i.e. Kruskal Wallis) was
used to determine the statistically significance differences
in mean values for the three hypertension stages. Mann-
Whitney test was used to determine the statistically
significance differences in means values for the two groups
in the gender, race and age groups. Statistical analysis was
performed by SPSS-Windows version 12. Results were
reported as mean values, standard deviation (SD), median
and mean rank. A p value < 0.05 was defined as statistically
significant.
RESULTS
From 1 January to 31 December 2007, 300 patients were
enrolled in the study. All of them were diagnosed with
hypertension and were receiving at least 1 antihypertensive
drug. Data from 300 patients were analyzed; 100 patients
were coded as prehypertension group, 100 as stage 1
hypertension group and 100 as stage 2-hypertension group.
The mean age was 53.53 (SD 9.58) years; 83% of the
patients were = 45 years old and the 17% were < 45 years
old. The majority of the patients (79.7%) were Malay,
followed by others (20.3%). Chinese, Indians and others
patients were treated as “Others” in the analysis because
of their small percentage in the whole sample. Females
represented approximately more than two thirds of the
patients (72.3%). The demographic and clinical features
of the 600 patients are reported in Table-1.
Direct costs
Mean total direct costs per patient per month were higher
in the higher blood pressure categories as shown in
Table -2. The hypertension related total direct costs per
month attributable to prehypertensive, stage 1 and stage 2
hypertensive patients were calculated to be RM 16.20, RM
17.43, and RM 27.22  respectively.
Among the three categories of hypertension, a significant
difference in the mean total monthly direct costs was
observed (Table 3). These results were significant in both
the main analysis and the sensitivity analysis.
Indirect costs
The value of productivity potentially lost due to
absenteeism from work due to hypertension was RM
176.59, RM 164.73 and RM 164.39 for prehypertensive,
stage 1 and stage 2 hypertensive patients respectively, as
shown in Table 4. There was no significant difference in
the total monthly indirect mean costs among the three
groups of hypertensive patients.
The total direct costs were RM 1612.38, RM 1741.85
and RM 2718.21 for the prehypertensive, stage 1 and stage
2 hypertensive groups respectively. The total indirect costs
were RM 8078.70, RM 6654.52 and RM 7511.41 (Table
5).
DISCUSSION
Hypertension stands as an important spot of worry for
economic evaluations because of the wide range of issues
involved for the individual and society. It is one of the
most expensive diseases as far as treatment is concerned,
as it generates higher health care expenses than those
produced by individuals with normal blood pressure.
11
Additionally, despite the existing guidelines for the
treatment of hypertension, its treatment is inadequate in
a large number of hypertensive individuals in Malaysia,
4
therefore causing major organ damages, mainly in patients
with higher or uncontrolled blood pressure. These
complications add huge costs to the overall cost of health
care; developments in the hypertension treatment process
3
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should decrease the occurrence of these complications and
consequently improve cost control.
The data collected in this cost of illness study are
observational, to be precise, they represent what actually
occurs in the real health care practice in Kuantan. Real-
world data are necessary for sound coverage, payment, and
reimbursement decision. They may offer apparent
advantage for understanding outcomes of treatment, for
instance, for patients excluded from clinical trials, patients
in actual clinical practice settings (vs. research settings),
and patients whom treatment is not determines by trial
protocol or practice guidelines.
12
Medications costs are frequently referred to as an important
cost driver in the treatment of hypertension.
13, 1
 In this
study, antihypertensive drugs accounted for 53.7%, 55.1%
and 72.4% of the prehypertension, stage 1 and stage 2
hypertension groups total direct cost. Medications costs
were the primary cost driver of the total costs.
In this cost of illness study, there was a positively association
between blood pressure and personal total monthly medical
costs. However, the medical costs attributable to combined
pre-hypertensive and stage 1 hypertensive patients were
higher than those attributable to stage 2 hypertensives
patients.
14,3 
 Total direct costs were increasing as the blood
pressure category increases.
14
Physician costs were higher in the prehypertension and
stage 1 hypertension groups in comparison to stage 2
hypertension group. The comparatively high physician
costs may be explained relatively by the fact that
hypertension was newly diagnosed in these patients
compared to patients with stage 2 hypertension.
15
From an individual patient point of view, medical costs
increase as blood pressure increases. Nevertheless, from
the point of view of the whole hypertensive population,
prehypertension and stage 1 hypertension has a large
economic impact, because the number of prehypertension
and stage 1 hypertension patients is much larger than that
of patients with stage 2 hypertension. The result of this
cost of illness study would expect a reduction in total direct
costs of the hypertension population if each patient’s blood
pressure to become controlled (<140 for systolic blood
pressure and < 90 for diastolic blood pressure). This
reduction in direct costs can be achieved by changing
lifestyle habits for example: reducing dietary sodium intake,
decreasing body weight, quitting smoking and reducing
alcohol intake.
16 
 In addition, anti-hypertensive
medications can lower the risk of cardiovascular mortality
in hypertensive individuals.
17
The mean total direct costs among the three stages of
hypertension were significantly different and this could
be due to the noticeable difference in the health care
resources consumed by hypertensive patients in each
different blood pressure categories.
In contrast to other studies,
 14,3
 this study the total direct
costs for men seem to be higher than those for women. A
possible but purely provisional explanation is that women
are more frequent users of health care, and hence their
high blood pressure is detected and drug therapy is initiated
and blood pressure is controlled in contrast to men who
are normally unaware of their blood pressure which is not
controlled and thus seeking more health care interventions
to control the blood pressure leading to higher direct costs.
Another reason might be considered is that, the female
subjects represented the majority of the study subjects,
which will affect the mean cost for the female category.
The indirect costs attributable to hypertension were higher
in prehypertension group than in the other two groups
(stage 1 and stage 2 hypertension) as shown in. This can
be explained by the fact that, newly diagnosed hypertension
patients might be visiting health care clinic more frequently
than those who are in other blood pressure groups.
Therefore they tend to be absent from their work places
more often than other hypertensive patients (stage 1 and
stage 2 hypertension) who are already on regular follow
up visits.
In spite of its limitation, this cost of illness study may be
the first to estimate both the direct and indirect costs
associated with hypertension in Malaysia. Although the
accuracy of the estimates maybe limited, it represents one
conservative method for determining the potential
magnitude of the economic burden imposed by
hypertension disease. Since the identification of an
appropriate sample size is an important issue concerning
study design when testing an economic hypothesis, as well
as an enough and adequate length of follow up, this study
should be considered as preliminary, nevertheless we believe
that it represents a useful step towards the evaluation of
the true cost of hypertension.
CONCLUSION
Hypertension treatment for the large number of people in
Malaysia creates an economic burden on health care
budgets and the whole nation economy. Cost of illness
studies are useful to estimate the actual direct and indirect
costs attributable to hypertension treatment. In spite of
its limitation, this cost of illness study is the first to estimate
both the direct and indirect costs associated with
hypertension in Malaysia.
The direct costs attributable to hypertension disease were
4
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increased as hypertension severity increase. In addition,
direct costs of hypertension were mainly dependant on
the antihypertensive agents’ costs. They were significantly
different among the three stages of hypertension. Indirect
costs were the highest in the prehypertension group of
patients followed by stage 1 and stage 2 hypertension. The
difference between the indirect costs among the three stages
was insignificant. High efforts should be made and taken
to prevent hypertension in order to reduce medical costs
that are directly related to hypertension. Efforts should
focus on improving the awareness of the both clinical and
economic benefits of preventing hypertension in the
society.
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